Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis
Authors
Keywords
Thyroid stimulating hormone, TSH, Ipilimumab, Hypophysitis, Hypopituitarism
Journal
Pituitary
Volume 21, Issue 3, Pages 274-282
Publisher
Springer Nature
Online
2018-01-29
DOI
10.1007/s11102-018-0866-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Baseline morning cortisol level as a predictor of pituitary-adrenal reserve: a comparison across three assays
- (2016) Emilia Sbardella et al. CLINICAL ENDOCRINOLOGY
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
- (2015) Anne Bertrand et al. BMC Medicine
- Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series
- (2015) T. Lam et al. INTERNAL MEDICINE JOURNAL
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
- (2015) Alexander Faje Pituitary
- Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study
- (2014) L. Min et al. CLINICAL CANCER RESEARCH
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- (2014) Mabel Ryder et al. ENDOCRINE-RELATED CANCER
- Detection of Pituitary Antibodies by Immunofluorescence: Approach and Results in Patients With Pituitary Diseases
- (2014) Adriana Ricciuti et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
- (2014) Alexander T. Faje et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Ipilimumab-induced hypophysitis: early Australian experience
- (2014) Sunita M C De Sousa et al. MEDICAL JOURNAL OF AUSTRALIA
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
- (2013) Caroline J. Voskens et al. PLoS One
- Depth and duration of hypoglycaemia achieved during the insulin tolerance test
- (2012) O. Ajala et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Association of Ipilimumab Therapy for Advanced Melanoma with Secondary Adrenal Insufficiency: A Case Series
- (2011) Le Min et al. Endocrine Practice
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma
- (2010) A. A. Sarnaik et al. CLINICAL CANCER RESEARCH
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search